Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis

Company Overview

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments.

Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection. The drug is designed to inhibit bacterial DNA polymerase IIIC, an enzyme involved in bacterial DNA replication, while potentially preserving beneficial bacteria in the gut.

The company’s development programs are focused primarily on the U.S. market and remain subject to clinical testing and regulatory review. Acurx is headquartered in New York and continues to advance ibezapolstat through clinical development while evaluating the broader potential of its antibiotic discovery platform.

Key Stats

• Today's Range: $1.04 to $1.10
• 50-Day Range: $1.04 to $1.47
• 52-Week Range: $1.04 to $7.54
• Volume: 63,194 shs
• Average Volume: 70,083 shs
• Market Capitalization: $5.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Acurx Pharmaceuticals Stock Analysis - MarketRank™

Acurx Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Acurx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Acurx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acurx Pharmaceuticals are expected to grow in the coming year, from ($2.00) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acurx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acurx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acurx Pharmaceuticals has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.75% of the float of Acurx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Acurx Pharmaceuticals has a short interest ratio ("days to cover") of 1.16, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Acurx Pharmaceuticals has recently decreased by 18.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acurx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Acurx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.00

News Sentiment

Acurx Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Acurx Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for ACXP on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.50% of the stock of Acurx Pharmaceuticals is held by insiders.

Percentage Held by Institutions

11.53% of the stock of Acurx Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/31/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ACXP
• CIK: 1736243
• Web: www.acurxpharma.com
• Phone: 917-533-1469
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -124.73%
• Return on Assets: -87.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.88
• Quick Ratio: 3.88

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.07 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 5,560,000
• Free Float: 5,198,000
• Market Cap: $5.78 million
• Optionable: No Data
• Beta: -2.05